RCMI Coordinating Center (RCMI CC) Header Logo

Jill Bargonetti

TitleProfessor of Biology
Faculty RankProfessor
InstitutionHunter College, CUNY
DepartmentBiological Sciences
AddressBelfer Research Building
413 East 69th Street
Room 400
New York NY 10021
Phone(212)896-0465
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionCUNY Graduate Center
    DepartmentBiology and Biochemistry

    TitleAdjunct Professor
    InstitutionWeill Cornell Medical College
    DepartmentCell Biology


    Collapse Biography 
    Collapse awards and honors
    1997Presidential Early Career Award for Scientists and Engineers , From President William J. Clinton
    1998Felix Gross Endowment Award Citation: For Outstanding Scholarly Achievement, CUNY Academy for the Humanities and Sciences
    1998New York Voice Award: in recognition of individuals who have made a significant improvement to the , New York Voice Award
    2001NYC Mayor’s Award, Young Investigator Category , NYC Mayor Rudolph Gulliani
    2001Outstanding Woman Scientist Award , Association for Women in Science
    2005Distinguished Alumni/ae Award, New York University Graduate School of Arts and Sciences
    2005Presidential Distinguished Alumni/ae Award , SUNY Purchase
    2011American Association for Cancer Research Minority-Serving Institution Faculty Scholar in Cancer Rese, International Conference on Frontiers in Basic Cancer Research.
    2014Jocelyn Spragg Invited Lecture: “Celebrating Diversity in the Biomedical Sciences”, Harvard University

    Collapse Overview 
    Collapse overview
    Jill Bargonetti is a Full Professor at The City University of New York (CUNY) at Hunter College and The Graduate Center in the PhD Programs of Biology and Biochemistry. In 2015 she joined the Cornell Medical Center Hunter College Belfer Research team as an Adjunct Assistant Professor of Cell and Developmental Biology. Since arriving at CUNY in 1994 Dr. Bargonetti has received numerous awards and recognitions. In 1997 she received a National Science Foundation Career Award and also received the Presidential Early Career Award for Scientists and Engineers from President William Clinton. She was a member of the National Cancer Policy Board from 2002 until 2005 (a board of the Institution of Medicine and National Research Council of the National Academies) and currently serves as a standing member on the National Institutes of Health, Tumor Cell Biology study section until 2018. Professor Bargonetti is an expert in the fields of p53 and MDM2 biology. She has carried out extensive research on the function of wild-type p53 (which assists in the suppression of tumor cells), on oncogenic mutant p53 function (which is a tumor promoter), and on the p53-dependent and p53-independent functions of MDM2. Dr. Bargonetti has been recognized for her outreach and teaching accomplishments at the graduate and undergraduate levels. Classes she has designed include an undergraduate curriculum using p53-biology as an undergraduate biology exercise (used in Biology 302 since 1997 and now in Biology 303). She recently developed a choreographic movement based class called “Choreographing Genomics” (Biology 175) that uses Post-Modern dance choreographic concepts for students to explore genomics and the relationship of gene regulation to Cancer Biology. Dr. Bargonetti has graduated fourteen PhD recipients. In addition numerous undergraduate students have worked with Dr. Bargonetti on research projects and she has trained many undergraduates on p53 biology in the coordinated laboratory and lecture courses Molecular Genetics and Cell Biology.

    Collapse Research 
    Collapse research activities and funding
    SC1CA137843     (BARGONETTI, JILL E.)Aug 6, 2008 - Jul 31, 2012
    NIH
    p53-Independent Cell Death Signaling by Mitomycin DNA Adducts
    Role: Principal Investigator
    R01CA239603     (BARGONETTI, JILL E.)Feb 6, 2020 - Jan 31, 2025
    NIH
    The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ellison V, Polotskaia A, Xiao G, Leybengrub P, Qiu W, Lee R, Hendrickson R, Hu W, Bargonetti J. A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN. bioRxiv. 2024 Jan 23. PMID: 38328189.
      Citations:    
    2. Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, Bargonetti J. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024 Mar 01; 584:216608. PMID: 38199587.
      Citations: 1     Fields:    
    3. Wang J, Chang CY, Yang X, Zhou F, Liu J, Bargonetti J, Zhang L, Xie P, Feng Z, Hu W. p53 suppresses MHC class II presentation by intestinal epithelium to protect against radiation-induced gastrointestinal syndrome. Nat Commun. 2024 Jan 02; 15(1):137. PMID: 38167344.
      Citations:    Fields:    Translation:AnimalsPHPublic Health
    4. Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Davis MB, Martin ML, Bargonetti J. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. bioRxiv. 2023 Jun 22. PMID: 38076873.
      Citations:    
    5. Lundine D, Annor GK, Chavez V, Maimos S, Syed Z, Jiang S, Ellison V, Bargonetti J. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose. Mol Cancer Res. 2022 Dec 02; 20(12):1799-1810. PMID: 36074101.
      Citations: 2     Fields:    Translation:Cells
    6. Canar J, Manandhar-Sasaki P, Bargonetti J. Mutant C. elegans p53 Together with Gain-of-Function GLP-1/Notch Decreases UVC-Damage-Induced Germline Cell Death but Increases PARP Inhibitor-Induced Germline Cell Death. Cancers (Basel). 2022 Oct 08; 14(19). PMID: 36230851.
      Citations:    
    7. Lama R, Xu C, Galster SL, Querol-Garc?a J, Portwood S, Mavis CK, Ruiz FM, Martin D, Wu J, Giorgi MC, Bargonetti J, Wang ES, Hernandez-Ilizaliturri FJ, Koudelka GB, Chemler SR, Mu?oz IG, Wang X. Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status. Front Oncol. 2022; 12:933446. PMID: 35992795.
      Citations:    
    8. Annor GK, Elshabassy N, Lundine D, Conde DG, Xiao G, Ellison V, Bargonetti J. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities. Front Cell Dev Biol. 2021; 9:772315. PMID: 34881245.
      Citations:    
    9. Wilson T, Pirovano G, Xiao G, Samuels Z, Roberts S, Viray T, Guru N, Zanzonico P, Gollub M, Pillarsetty NVK, Reiner T, Bargonetti J. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. Mol Pharm. 2021 09 06; 18(9):3418-3428. PMID: 34318678.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    10. Ellison V, Annor GK, Freedman C, Xiao G, Lundine D, Freulich E, Prives C, Bargonetti J. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity. Oncotarget. 2021 Jun 08; 12(12):1128-1146. PMID: 34136083.
      Citations: 4     Fields:    
    11. Xiao G, Annor GK, Fung K, Kein?nen O, Zeglis BM, Bargonetti J. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. Mol Pharm. 2021 01 04; 18(1):338-346. PMID: 33289569.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    12. Kim JY, Lee R, Xiao G, Forbes D, Bargonetti J. MDM2-C Functions as an E3 Ubiquitin Ligase. Cancer Manag Res. 2020; 12:7715-7724. PMID: 32904724.
      Citations:    
    13. Farooqi K, Ghazvini M, Pride LD, Mazzella L, White D, Pramanik A, Bargonetti J, Moore CW. A Protein in the Yeast Saccharomyces cerevisiae Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor. Biomolecules. 2020 03 07; 10(3). PMID: 32156076.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    14. Xiao G, Lundine D, Annor GK, Canar J, Ellison V, Polotskaia A, Donabedian PL, Reiner T, Khramtsova GF, Olopade OI, Mazo A, Bargonetti J. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2020 02 01; 80(3):394-405. PMID: 31776133.
      Citations: 31     Fields:    Translation:HumansCells
    15. Gao C, Xiao G, Bargonetti J. Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. Oncotarget. 2019 Aug 20; 10(49):5007-5010. PMID: 31489110.
      Citations: 2     Fields:    
    16. Bargonetti J, Prives C. Gain-of-function mutant p53: history and speculation. J Mol Cell Biol. 2019 07 19; 11(7):605-609. PMID: 31283823.
      Citations: 41     Fields:    Translation:HumansAnimals
    17. Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Res. 2019 01 14; 21(1):5. PMID: 30642351.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    18. Loo LWM, Gao C, Shvetsov YB, Okoro DR, Hernandez BY, Bargonetti J. MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population. Breast Cancer Res Treat. 2019 Feb; 174(1):257-269. PMID: 30470976.
      Citations: 5     Fields:    Translation:Humans
    19. Kundu N, Brekman A, Kim JY, Xiao G, Gao C, Bargonetti J. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. Oncotarget. 2017 Jul 18; 8(29):47916-47930. PMID: 28615518.
      Citations: 17     Fields:    Translation:HumansCells
    20. Qiu WG, Polotskaia A, Xiao G, Di L, Zhao Y, Hu W, Philip J, Hendrickson RC, Bargonetti J. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. NPJ Breast Cancer. 2017; 3. PMID: 28232952.
      Citations:    
    21. Shtraizent N, Matsui H, Polotskaia A, Bargonetti J. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. Int J Environ Res Public Health. 2015 Dec 22; 13(1):ijerph13010022. PMID: 26703669.
      Citations: 14     Fields:    Translation:HumansCells
    22. Rosso M, Polotskaia A, Bargonetti J. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget. 2015 Oct 27; 6(33):34573-91. PMID: 26416444.
      Citations: 2     Fields:    Translation:HumansCells
    23. Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, B?rresen-Dale AL, Neilsen PM, Prives C. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 2015 Jun 15; 29(12):1298-315. PMID: 26080815.
      Citations: 75     Fields:    Translation:HumansCells
    24. Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, Bargonetti J. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc Natl Acad Sci U S A. 2015 Mar 17; 112(11):E1220-9. PMID: 25733866.
      Citations: 52     Fields:    Translation:HumansCells
    25. Xiao G, Kue P, Bhosle R, Bargonetti J. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. Cell Cycle. 2015; 14(5):744-54. PMID: 25565400.
      Citations: 8     Fields:    Translation:HumansCells
    26. Shi M, Shtraizent N, Polotskaia A, Bargonetti J, Matsui H. Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure. PLoS One. 2014; 9(6):e99351. PMID: 24937470.
      Citations: 4     Fields:    Translation:HumansCells
    27. Hoffman S, Martin D, Mel?ndez A, Bargonetti J. C. elegans CEP-1/p53 and BEC-1 are involved in DNA repair. PLoS One. 2014; 9(2):e88828. PMID: 24586407.
      Citations: 10     Fields:    Translation:AnimalsCells
    28. Rosso M, Okoro DE, Bargonetti J. Splice variants of MDM2 in oncogenesis. Subcell Biochem. 2014; 85:247-61. PMID: 25201199.
      Citations: 11     Fields:    Translation:HumansCells
    29. Okoro DR, Arva N, Gao C, Polotskaia A, Puente C, Rosso M, Bargonetti J. Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator. PLoS One. 2013; 8(10):e77643. PMID: 24147044.
      Citations: 17     Fields:    Translation:HumansCells
    30. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C, Avantaggiati ML. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2012 Dec 01; 11(23):4436-46. PMID: 23151455.
      Citations: 79     Fields:    Translation:HumansAnimalsCells
    31. Polotskaia A, Hoffman S, Krett NL, Shanmugam M, Rosen ST, Bargonetti J. 8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers. Mol Cancer Ther. 2012 Nov; 11(11):2495-504. PMID: 22973058.
      Citations: 6     Fields:    Translation:HumansCells
    32. Okoro DR, Rosso M, Bargonetti J. Splicing up mdm2 for cancer proteome diversity. Genes Cancer. 2012 Mar; 3(3-4):311-9. PMID: 23150764.
      Citations:    
    33. Freed-Pastor WA, Mizuno H, Zhao X, Langer?d A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, B?rresen-Dale AL, Levine AJ, Bargonetti J, Prives C. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012 Jan 20; 148(1-2):244-58. PMID: 22265415.
      Citations: 480     Fields:    Translation:HumansCells
    34. Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res. 2011 Jan 11; 13(1):R3. PMID: 21223569.
      Citations: 55     Fields:    Translation:HumansCells
    35. Bargonetti J, Champeil E, Tomasz M. Differential toxicity of DNA adducts of mitomycin C. J Nucleic Acids. 2010 Jul 29; 2010. PMID: 20798760.
      Citations:    
    36. Boamah EK, Brekman A, Tomasz M, Myeku N, Figueiredo-Pereira M, Hunter S, Meyer J, Bhosle RC, Bargonetti J. DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1. Chem Res Toxicol. 2010 Jul 19; 23(7):1151-62. PMID: 20536192.
      Citations: 13     Fields:    Translation:HumansCells
    37. Paz MM, Ladwa S, Champeil E, Liu Y, Rockwell S, Boamah EK, Bargonetti J, Callahan J, Roach J, Tomasz M. Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography/ electrospray tandem mass spectrometry. Chem Res Toxicol. 2008 Dec; 21(12):2370-8. PMID: 19053323.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    38. Arva NC, Talbott KE, Okoro DR, Brekman A, Qiu WG, Bargonetti J. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethn Dis. 2008; 18(2 Suppl 2):S2-1-8. PMID: 18646312.
      Citations: 13     Fields:    Translation:HumansCells
    39. Boamah EK, White DE, Talbott KE, Arva NC, Berman D, Tomasz M, Bargonetti J. Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways. ACS Chem Biol. 2007 Jun 15; 2(6):399-407. PMID: 17530733.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    40. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene. 2006 Nov 23; 25(55):7305-10. PMID: 16785993.
      Citations: 93     Fields:    Translation:HumansCells
    41. White DE, Talbott KE, Arva NC, Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res. 2006 Apr 01; 66(7):3463-70. PMID: 16585169.
      Citations: 17     Fields:    Translation:HumansCells
    42. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005 Jul 22; 280(29):26776-87. PMID: 15908423.
      Citations: 52     Fields:    Translation:HumansCells
    43. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602. PMID: 15550242.
      Citations: 525     Fields:    Translation:HumansAnimalsCells
    44. Hui L, Abbas T, Pielak RM, Joseph T, Bargonetti J, Foster DA. Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Mol Cell Biol. 2004 Jul; 24(13):5677-86. PMID: 15199126.
      Citations: 21     Fields:    Translation:AnimalsCells
    45. Abbas T, White D, Hui L, Yoshida K, Foster DA, Bargonetti J. Inhibition of human p53 basal transcription by down-regulation of protein kinase Cdelta. J Biol Chem. 2004 Mar 12; 279(11):9970-7. PMID: 14699137.
      Citations: 16     Fields:    Translation:HumansCells
    46. Molina MP, Cain C, Bargonetti J. In vivo footprinting and DNA affinity chromatography for analysis of p53 DNA binding ability. Methods Mol Biol. 2003; 234:151-70. PMID: 12824531.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    47. Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M, Bargonetti J. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem. 2002 Oct 25; 277(43):40513-9. PMID: 12183457.
      Citations: 16     Fields:    Translation:HumansCells
    48. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol. 2002 Jan; 14(1):86-91. PMID: 11790986.
      Citations: 93     Fields:    Translation:HumansCells
    49. Houser S, Koshlatyi S, Lu T, Gopen T, Bargonetti J. Camptothecin and Zeocin can increase p53 levels during all cell cycle stages. Biochem Biophys Res Commun. 2001 Dec 21; 289(5):998-1009. PMID: 11741290.
      Citations: 3     Fields:    Translation:HumansCells
    50. Chicas A, Molina P, Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun. 2000 Dec 20; 279(2):383-90. PMID: 11118296.
      Citations: 35     Fields:    Translation:HumansCells
    51. Xiao G, Chicas A, Olivier M, Taya Y, Tyagi S, Kramer FR, Bargonetti J. A DNA damage signal is required for p53 to activate gadd45. Cancer Res. 2000 Mar 15; 60(6):1711-9. PMID: 10749144.
      Citations: 17     Fields:    Translation:HumansCells
    52. Boydston-White S, Gopen T, Houser S, Bargonetti J, Diem M. Infrared spectroscopy of human tissue. V. Infrared spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. Biospectroscopy. 1999; 5(4):219-27. PMID: 10478952.
      Citations: 25     Fields:    Translation:HumansCells
    53. Xiao G, White D, Bargonetti J. p53 binds to a constitutively nucleosome free region of the mdm2 gene. Oncogene. 1998 Mar 05; 16(9):1171-81. PMID: 9528859.
      Citations: 9     Fields:    Translation:AnimalsCells
    54. Bargonetti J, Chicas A, White D, Prives C. p53 represses Sp1 DNA binding and HIV-LTR directed transcription. Cell Mol Biol (Noisy-le-grand). 1997 Nov; 43(7):935-49. PMID: 9449526.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    55. Chen X, Bargonetti J, Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res. 1995 Oct 01; 55(19):4257-63. PMID: 7671232.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    56. Prives C, Bargonetti J, Farmer G, Ferrari E, Friedlander P, Wang Y, Jayaraman L, Pavletich N, Hubscher U. DNA-binding properties of the p53 tumor suppressor protein. Cold Spring Harb Symp Quant Biol. 1994; 59:207-13. PMID: 7587071.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    57. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 1993 Dec; 7(12B):2565-74. PMID: 8276239.
      Citations: 83     Fields:    Translation:HumansCells
    58. Bargonetti J, Wang PZ, Novick RP. Measurement of gene expression by translational coupling: effect of copy mutations on pT181 initiator synthesis. EMBO J. 1993 Sep; 12(9):3659-67. PMID: 8253088.
      Citations: 6     Fields:    Translation:Cells
    59. Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A. 1993 Apr 15; 90(8):3319-23. PMID: 8475074.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    60. Bargonetti J, Reynisd?ttir I, Friedman PN, Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 1992 Oct; 6(10):1886-98. PMID: 1398068.
      Citations: 94     Fields:    Translation:HumansAnimalsCells
    61. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature. 1992 Jul 02; 358(6381):83-6. PMID: 1614538.
      Citations: 193     Fields:    Translation:HumansAnimalsCells
    62. Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 1992 Jul; 6(7):1143-52. PMID: 1628822.
      Citations: 105     Fields:    Translation:HumansAnimalsCells
    63. Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell. 1991 Jun 14; 65(6):1083-91. PMID: 1646078.
      Citations: 132     Fields:    Translation:AnimalsCells
    64. Prives C, Bargonetti J, Friedman PN, Manfredi JJ, Wang EH. Functional consequences of the interactions of the p53 tumor suppressor protein and SV40 large tumor antigen. Cold Spring Harb Symp Quant Biol. 1991; 56:227-35. PMID: 1668081.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    65. Noirot P, Bargonetti J, Novick RP. Initiation of rolling-circle replication in pT181 plasmid: initiator protein enhances cruciform extrusion at the origin. Proc Natl Acad Sci U S A. 1990 Nov; 87(21):8560-4. PMID: 2236066.
      Citations: 43     Fields:    Translation:Cells
    66. Iordanescu S, Bargonetti J. Staphylococcus aureus chromosomal mutations that decrease efficiency of Rep utilization in replication of pT181 and related plasmids. J Bacteriol. 1989 Aug; 171(8):4501-3. PMID: 2753862.
      Citations: 11     Fields:    Translation:Cells
    Bargonetti's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (260)
    Explore
    _
    Co-Authors (6)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support